LexDanaLexDanabeta
Inventor

Xiong Cai

Inventor
Bedford, MA, US

Overview

67→
Patents
1994–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 67 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds41%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes17%
Y02ATechnologies for adaptation to climate change7%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
10,844,056Fused amino pyridine as HSP90 inhibitors202010,676,482Phosphoinositide 3-kinase inhibitors with a zinc binding moiety202010,543,197Phosphoinositide 3-kinase inhibitor with a zinc binding moiety202010,428,068Fused amino pyridine as HSP90 inhibitors201910,336,770Phosphoinositide 3-kinase inhibitors with a zinc binding moiety201910,214,514Hedgehog antagonists having zinc binding moieties201910,183,941Pyrimidine or pyridopyridone compound and application thereof201910,111,864Phosphoinositide 3-kinase inhibitor with a zinc binding moiety201810,035,797Fused amino pyridine as HSP90 inhibitors20189,725,461'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20179,708,299'Hedgehog antagonists having zinc binding moieties'20179,657,032'Phosphoinositide 3-kinase inhibitor with a zinc binding moiety'20179,630,965'Fused amino pyridine as HSP90 inhibitors'20179,402,832'Fused amino pyridine as HSP90 inhibitors'20169,249,156'Phosphoinositide 3-kinase inhibitor with a zinc binding moiety'20169,169,244'Tyrosine kinase inhibitors containing a zinc binding moiety'20159,108,929'Quinazoline based EGFR inhibitors'20159,040,556'Fused amino pyridine as HSP90 inhibitors'20159,024,024'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20158,975,401'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20158,906,909'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20148,846,912'Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety'20148,722,703'Fused amino pyridines for the treatment of brain tumors'20148,710,219'Phosphoinositide 3-kinase inhibitor with a zinc binding moiety'20148,691,820'CDK inhibitors'20148,604,044'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,586,605'Fused amino pyridine as HSP90 inhibitors'20138,563,741'CDK inhibitors containing a zinc binding moiety'20138,518,910'Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,461,157'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20138,455,506'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20138,426,419'Tyrosine kinase inhibitors containing a zinc binding moiety'20138,367,663'Phosphoinositide 3-kinase inhibitors with a zinc binding moiety'20138,349,856'Quinazoline based EGFR inhibitors'20138,324,240'Fused amino pyridine as HSP90 inhibitors'20128,273,785'Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety'20128,119,616'Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety'20127,977,347'Quinazoline based EGFR inhibitors'20117,928,136'Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety'20117,888,361'Tyrosine kinase inhibitors containing a zinc binding moiety'20117,846,938'Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety'20107,547,781'Quinazoline based EGFR inhibitors containing a zinc binding moiety'20096,894,059'Compounds and methods for treatment of asthma, allergy and inflammatory disorders'20056,797,713'Compounds and methods for treatment of asthma, allergy and inflammatory disorders'20046,686,502'Compounds and methods for treatment of asthma, allergy and inflammatory disorders'20046,569,895'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20036,555,550'Musarinic agonists and antagonists'20036,451,801'Compounds and methods for treatment of asthma, allergy and inflammatory disorders'20026,423,842'Muscarinic agonists and antagonists'20026,420,392'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20026,323,194'Muscarinic agonists and antagonists'20016,294,574'Compounds and methods for the treatment of inflammatory and immune disorders'20016,251,916'Muscarinic agonists and antagonists'20016,201,016'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20016,093,724'Muscarinic agonists and antagonists'20006,025,384'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'20005,856,323'Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase'19995,792,776'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19985,780,503'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19985,750,565'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19985,741,809'Compounds and methods for the treatment of cardiovascular inflammatory and immune disorders'19985,703,093'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19975,681,966'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19975,648,486'Compounds and methods for the treatment of inflammatory and immune disorders'19975,463,083'Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders'19955,434,151'Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase'19955,358,938'Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2001Patents assigned to CYTOMED INC (13)· patent assignee history
1994–2001Based in Allston, MA, US· patent location history
1995–2003Based in Framingham, MA, US· patent location history
2000–2013Based in Belmont, MA, US· patent location history
2009–2020Patents assigned to CURIS INC (41)· patent assignee history
2012–2014Patents assigned to CAI XIONG (15)· patent assignee history
2012–2014Patents assigned to QIAN CHANGGENG (15)· patent assignee history
2012–2014Patents assigned to ZHAI HAIXIAO (11)· patent assignee history
2013–2020Based in Bedford, MA, US· patent location history
2019Based in Guangdong, CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CURIS INC412009–2020
CAI XIONGself152012–2014
QIAN CHANGGENG152012–2014
CYTOMED INC131994–2001
ZHAI HAIXIAO112012–2014
Locations
LocationPatentsSpan
Bedford, Massachusetts, US302013–2020
Belmont, Massachusetts, US202000–2013
Framingham, Massachusetts, US111995–2003
Allston, Massachusetts, US51994–2001
Guangdong, CN12019